Surgery for cancer: a trigger for metastases

S Tohme, RL Simmons, A Tsung - Cancer research, 2017 - AACR
S Tohme, RL Simmons, A Tsung
Cancer research, 2017AACR
Surgery is a crucial intervention and provides a chance of cure for patients with cancer. The
perioperative period is characterized by an increased risk for accelerated growth of
micrometastatic disease and increased formation of new metastatic foci. The true impact for
cancer patients remains unclear. This review summarizes the often fragmentary clinical and
experimental evidence supporting the role of surgery and inflammation as potential triggers
for disease recurrence. Surgery induces increased shedding of cancer cells into the …
Abstract
Surgery is a crucial intervention and provides a chance of cure for patients with cancer. The perioperative period is characterized by an increased risk for accelerated growth of micrometastatic disease and increased formation of new metastatic foci. The true impact for cancer patients remains unclear. This review summarizes the often fragmentary clinical and experimental evidence supporting the role of surgery and inflammation as potential triggers for disease recurrence. Surgery induces increased shedding of cancer cells into the circulation, suppresses antitumor immunity allowing circulating cells to survive, upregulates adhesion molecules in target organs, recruits immune cells capable of entrapping tumor cells, and induces changes in the target tissue and in the cancer cells themselves to enhance migration and invasion to establish at the target site. Surgical trauma induces local and systemic inflammatory responses that can also contribute to the accelerated growth of residual and micrometastatic disease. Furthermore, we address the role of perioperative factors, including anesthesia, transfusions, hypothermia, and postoperative complications, as probable deleterious factors contributing to early recurrence. Through the admittedly limited understanding of these processes, we will attempt to provide suggestions for potential new therapeutic approaches to target the protumorigenic perioperative window and ultimately improve long-term oncological outcomes. Cancer Res; 77(7); 1548–52. ©2017 AACR.
AACR